Wei-Ying Kuo
Overview
Explore the profile of Wei-Ying Kuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng R, de Rutte J, Ito C, Ott A, Bosler L, Kuo W, et al.
Nat Commun
. 2023 Jun;
14(1):3567.
PMID: 37322036
The secreted products of cells drive many functions in vivo; however, methods to link this functional information to surface markers and transcriptomes have been lacking. By accumulating secretions close to...
2.
Hsieh H, Kuo W, Lin J, Chen H, Hsu H, Wu C
ACS Omega
. 2022 Sep;
7(35):31529-31537.
PMID: 36092556
Patients with prostate-specific membrane antigen (PSMA)-positive tumors can benefit from PSMA-targeted therapy; thus, we have constructed a phage-displayed synthetic antibody library for the production of novel PSMA antibodies with superior...
3.
Hsu H, Tung C, Yu C, Chen C, Chen H, Huang Y, et al.
Sci Rep
. 2021 Jul;
11(1):15430.
PMID: 34326410
Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody-drug conjugates (ADCs) targeting MSLN...
4.
Choi S, Matta H, Gopalakrishnan R, Natarajan V, Gong S, Jeronimo A, et al.
Sci Rep
. 2021 May;
11(1):10002.
PMID: 33976304
Cytotoxicity assays are essential for the testing and development of novel immunotherapies for the treatment of cancer. We recently described a novel cytotoxicity assay, termed the Matador assay, which was...
5.
Wu C, Lin J, Chang W, Hsieh C, Wu C, Chen H, et al.
Colloids Surf B Biointerfaces
. 2019 Aug;
183:110387.
PMID: 31394419
Successful boron neutron capture therapy (BNCT) requires sufficient and specific delivery of boron atoms to malignant cells. Gold nanoparticles (AuNPs) have been used as a useful delivery system for selectively...
6.
Jian J, Chen H, Chiu Y, Peng H, Tung C, Chen I, et al.
MAbs
. 2018 Dec;
11(2):373-387.
PMID: 30526270
Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed...
7.
Kuo W, Hsu H, Wu C, Chen H, Chou Y, Tsou Y, et al.
MAbs
. 2018 Oct;
11(1):153-165.
PMID: 30365359
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced...
8.
Kuo W, Lin J, Hsu H, Chen H, Yang A, Wu C
Sci Rep
. 2018 Sep;
8(1):13735.
PMID: 30214017
Human epidermal growth factor receptor 2 (HER2) overexpression occurs in various types of cancers. Regarding the anti-HER2 targeted therapies showed superior treatment outcomes in several (pre)clinical studies, we used multimodality...
9.
Kuo W, Hwu L, Wu C, Lee J, Chang C, Liu R
Theranostics
. 2017 Mar;
7(3):647-663.
PMID: 28255357
Triple-negative breast cancer (TNBC) represents approximately 20% of all breast cancers and appears resistance to conventional cytotoxic chemotherapy, demonstrating a particularly poor prognosis and a significantly worse clinical outcome than...
10.
Kuo W, Wu C, Hwu L, Lee J, Tsai C, Lin K, et al.
Oncotarget
. 2015 Mar;
6(11):8663-75.
PMID: 25796627
Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with tumor relapse. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACI), is currently being used in...